ArticleJournal of inflammation research2026
Protective Effects of CR6-Interacting Factor 1 Against Angiotensin II-Induced Atrial Fibrillation by Regulating the SIRT1/eNOS Signaling Pathway and Cardiomyocyte Remodeling.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is a common arrhythmia associated with myocardial injury, oxidative stress, and inflammatory remodeling. Mitochondrial protein CR6-interacting factor 1 (CRIF1) has emerged as a potential regulator of cardiomyocyte homeostasis; however, its role in AF remains unclear. Methods: An AF model was established in C57BL/6 mice via subcutaneous infusion of angiotensin II (Ang II, 2.0 mg/kg/day) for 28 days. CRIF1 expression levels and its functional effects were evaluated in atrial tissue and Ang II-treated HL-1 cardiomyocytes using RT-qPCR, immunohistochemistry, ELISA, TUNEL, and DHE staining. CRIF1 was overexpressed to assess its effects on the SIRT1/eNOS pathway, apoptosis, hypertrophy, inflammation, and oxidative stress. Results: Ang II infusion promoted atrial remodeling and increased susceptibility to atrial fibrillation. During electrophysiological assessment, AF episodes were triggered by transesophageal burst pacing, revealing prolonged AF duration, increased AF inducibility, elevated creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH) levels, and enhanced atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) expression in Ang II-treated mice compared with controls. CRIF1 expression was markedly downregulated in the atrial tissue of AF mice and Ang II-treated HL-1 cells. CRIF1 overexpression activates the SIRT1/eNOS pathway, attenuates cardiomyocyte apoptosis, and reduces Ang II-induced hypertrophy. Furthermore, CRIF1 suppressed the expression of inflammatory cytokines (TNF-α, IL-1β, and IL-6) and diminished intracellular reactive oxygen species accumulation, thereby restoring antioxidant enzyme activity and nitric oxide (NO) production. The protective effects of CRIF1 on apoptosis are largely dependent on SIRT1 signaling. Conclusion: CRIF1 plays a critical protective role in Ang II-induced atrial remodeling by activating SIRT1/eNOS signaling and mitigating oxidative stress, inflammation, hypertrophy, and apoptosis. These findings highlight CRIF1 as a potential therapeutic target for preventing AF and its associated cardiac injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.